pharmacokinetics of glp 1 receptor agonists A Comprehensive Review on the and Drug−Drug Interactions Approved GLP-1 and a Dual GLP-1/GIP Receptor Agonist Emerging Trends in the Development

The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006

Data Synthesis Twenty-two reports and six prescribing sheets were included

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.

Learn the differences, costs, side effects, and which is best for you.

Our blog series on GLP-1 agonists for weight loss is aimed at unpacking the science behind this new frontier in weight management, presenting a detailed overview of how they work, their efficacy, and their role in a holistic approach to health and wellness.